Search for: "In re: The Goldman Sachs Group, Inc. Shareholder Litigation"
Results 21 - 30
of 30
Sorted by Relevance
|
Sort by Date
24 Aug 2022, 9:01 pm
” Without admitting or denying the SEC’s findings, BNY Mellon agreed to a cease-and-desist order, censure, and payment of a $1.5 million penalty.[14] On June 10, 2022, the Wall Street Journal reported that the SEC was investigating Goldman Sachs Group Inc. for its management of ESG investment funds. [read post]
15 Sep 2011, 8:44 am
Iowa) of the Senate's Committee on the Judiciary, asked SEC Chairman Mary Schapiro whether the Commission had destroyed files relating to some of its more high-profile and controversial matters, such as its investigations of Bernie Madoff, Goldman Sachs, Bank of America, Lehman Brothers and others. [read post]
23 Feb 2010, 6:16 am
Shareholder Engagement. [read post]
31 Jan 2024, 9:01 pm
Goldman Sachs Group Inc. [read post]
22 Apr 2024, 1:11 pm
For example, in In re GoHealth, Inc. [read post]
18 Mar 2008, 11:08 pm
, Inc., Court of Chancery C.A. [read post]
3 Mar 2012, 4:58 pm
In 2007 shareholder litigation over a leveraged buyout involving The Topps Company, Inc., he basically told New York state court judge Herbert Cahn to keep his mitts off this dispute when different shareholder groups filed challenges to the deal in New York and Delaware. [read post]
22 Oct 2011, 12:30 pm
Assink takes note of an interesting opinion from new Delaware Vice Chancellor Glasscock: I will let the introductory words written by the new Vice-Chancellor Glasscock in In re The Goldman Sachs Group, Inc. [read post]
19 Apr 2008, 8:50 am
Weisman, Partner;former Managing Partner, China offices, Baker & McKenzie Mark Kirsch, Chair of Global Litigation and Dispute Resolution, Clifford Chance Stephen Denyer, International Development Partner, Allen & Overy Andrew Grech, Managing Director, Slater & Gordon Steven Mark, Legal Services Commissioner, New South Wales, Australia Osama Rahman, Ministry of Justice, United Kingdom Yours Truly Anthony… [read post]
13 Jun 2008, 3:40 am
: (Patent Docs), Generic drug developers will continue to take advantage of global demand for lower-priced drugs, with Teva poised to maintain lead position says Goldman Sachs analyst: (GenericsWeb), Daiichi Sankyo takeover of Ranbaxy: (Profitability through Simplicity), (Spicy IP), (GenericsWeb), Canada: Generics to penetrate 26% pharma market in Canada says RNCOS research: (GenericsWeb), Canada: Generic drug makers spreading misinformation about patent regulation amendments to… [read post]
